ReviewCurrent rheumatology reports2009
Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs.
Review in Current rheumatology reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative.Rheumatology (Oxford, England) · 2012Pooled it
- Dexamethasone and diclofenac intramuscular mixture injection and risk of death: A case series study.Clinical case reports · 2021Article
- Increased risk of stroke among patients with ankylosing spondylitis: a population-based matched-cohort study.Rheumatology international · 2014Article
- Cardiac safety of diclofenac at a single dose in ram.TheScientificWorldJournal · 2013Article
- Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence.BMC cardiovascular disorders · 2012Article
- Are traditional NSAIDs prescribed appropriately among French elderly with osteoarthritis? Results from the CADEUS cohort.European journal of clinical pharmacology · 2011Article
- Thromboxane and the thromboxane receptor in cardiovascular disease.Clinical lipidology · 2010Article
- Update on the management of pain in arthritis and the use of cyclooxygenase-2 inhibitors.Current pain and headache reports · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the introduction of selective cyclooxygenase-2 inhibitors (coxibs), there has been an ongoing discussion about the cardiovascular (CV) safety of coxibs and the traditional nonsteroidal anti-inflammatory drugs (NSAIDs). Available data about the CV safety of NSAIDs come mostly from meta-analyses and a few clinical trials. Current evidence suggests that NSAIDs may increase the risk of CV events. Naproxen might be associated with lower risk, but available data are not conclusive. Recent recommendations on the treatment of patients with NSAIDs favor the use of naproxen in patients with increased CV risk. Therefore, this review focuses on data about naproxen and examines CV risk with ibuprofen and non-naproxen NSAIDs. In addition, data about CV safety of paracetamol (acetaminophen) are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.